Skip to main content

Expert conversations highlighting emerging research and clinical strategies tackling a variety of diseases and topics using stem cell techniques.

Join us on Zoom for conversations on cutting edge stem cell research.  These lectures will provide an accessible portal to learn about the amazing work being done at UC San Diego.

 

 

Speakers' background:


Davey Smith, MD, MAS, is an infectious disease specialist and translational research virologist. In his translational research, he uses basic science techniques to answer clinically relevant questions. Dr. Smith's primary research involves both figuring out how to stop the transmission of HIV and curing HIV, and he has published over 200 scientific publications in these areas. In 2010, Dr. Smith was named HIV Researcher of the Year by the HIV Medical Association, and he became the co-director and principal investigator of the San Diego Center for AIDS Research (CFAR) in 2016.

Since the outbreak of SARS-CoV-2 in 2019, Dr. Smith has been actively engaged in the international effort to find safe and effective treatments. In particular, he is the international protocol chair for the ACTIV-2 treatment study, which is a part of the US government's Operation Warp Speed. This study is designed to find effective therapies for persons with early COVID-19.

The Davey Lab at UC San Diego applies translational research techniques to the study of viruses. Since the early 2000s, the lab has focused on studying HIV transmission, superinfection, co-infection, and the latent reservoir. Underlying all HIV research within the Davey Lab is the ongoing search for a preventative vaccine and a permanent cure.

Translational research contributes to and borrows from laboratory, bedside, and community medicine to develop new approaches to treating and curing disease.


 

Sheldon Morris, M.D. is a board-certified family medicine doctor. He provides primary care for patients of all ages, including preventive care and treatment of acute and chronic diseases. He has special training in preventive medicine.

Dr. Morris has served on the faculty of UC San Diego School of Medicine since 2006 and is currently involved in clinical practice, teaching and research. His research work includes infectious disease epidemiology. He is especially interested in the epidemiology, natural history, and prevention of sexually transmitted infections (STI) and HIV.

As an associate professor of family medicine and public health, he is involved in training medical students, residents, and fellows at UC San Diego School of Medicine.

Prior to joining UC San Diego Health, Dr. Morris worked in both private practice and public health clinics. He has been a family physician since 1991. He has been involved in the clinical care of individuals infected with HIV and HCV and has worked in youth programs for reproductive health.

Dr. Morris completed his fellowship training at the State of California Department of Public Health STD Control Branch and his residency training in preventive medicine at UC San Francisco School of Medicine. He earned his master's degree in quantitative methods at Harvard School of Public Health.


 

Robert "Chip" Schooley, M.D., currently serves as Distinguished Professor of Medicine and Senior Director of International Initiatives at the University of California San Diego.

 His research efforts are directed at the pathogenesis and therapy of RNA virus infections. He has been heavily involved in the development of antiviral chemotherapy directed at HIV, HCV, and the herpes group viruses as well as in research, teaching, and infrastructure building efforts in sub-Saharan Africa. Over the past several years, he has become interested in the use of viruses as therapeutic agents – namely the use of bacteriophages to treat multidrug-resistant bacterial infections. 

He became Head of the Division of Infectious Diseases at the University of Colorado in 1990. He led the NIH’s AIDS Clinical Trials Group (ACTG) from 1995 until 2002 during which time the ACTG performed many of the seminal studies that defined modern antiretroviral chemotherapy. He then led the ACTG in its expansion from a domestic US research operation into one with a global reach. He was recruited to the University of California San Diego and served as Head of UCSD’s Infectious Diseases Division until 2017. He now serves as Senior Director of International Initiatives for the University of California San Diego. His laboratory is engaged in the discovery of orally bioavailable anti-coronavirus compounds. He has become deeply engaged in the University’s response to the SARS CoV-2 outbreak.


 

 

Past Seminars


December 17, 2020: Prostate Disease

J. Kellogg Parsons, M.D., MHS, Rana R. McKay, M.D., and Christina Jamieson, Ph.D. discussed the next generation of treatments for Prostate Cancer.


October 22, 2020: Precision Immunotherapy: 

Ezra Cohen, M.D. & Judy Varner, Ph.D. on how Precision Immunotherapy can harness the body’s immune system to kill cancer cells.


August 6, 2020: Parkinson’s Disease: 

Irene Litvan, M.D., Don Cleveland, Ph.D., and David Higgins, Ph.D., discussed the next generation of treatments for Parkinson’s Disease and offered a patient’s perspective.